Business
Cannabics Pharmaceuticals Receives Patent "Notice of Allowance" From The Mexican Patent and Trademark Office (IMPI)
Cannabics Pharmaceuticals Receives Patent "Notice of Allowance" From The Mexican Patent and Trademark Office (IMPI).
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals Receives Patent \"Notice of Allowance\" From The Mexican Patent and Trademark Office (IMPI)\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCannabics Pharmaceuticals Receives Patent \"Notice of Allowance\" From The Mexican Patent and Trademark Office (IMPI)\nPR Newswire\nTEL AVIV, Israel and BETHESDA, Md., May 6, 2021\n\n\n\nTEL AVIV, Israel and BETHESDA, Md., May 6, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it had received \"Notice of Allowance\" from the Mexican Patent and Trademark Office (IMPI) in relation to the company's patent titled: 'System and method for high throughput screening of cancer cells'. The decision of the Mexican patent authority follows the European Patent Office (EPO) \"Intention to Grant a European Patent\" notice to the company from October 2020, concerning the same patent application.\n\n \n \n \n \n \n \n\n \nEyal Barad, Cannabics Pharmaceuticals' co-founder and CEO commented: \"This patent application is a great example of Cannabics's innovative and novel approach to the drug discovery process in our field. The patent was already granted in Israel and in South Africa, and we have been notified of intention to grant in Europe and now also in Mexico. This opens many interesting opportunities for the company in these markets, which we intend to develop and grow.\"\nAbout Cannabics Pharmaceuticals:\nCannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a U.S. public company and a global leader in the development of cancer related cannabinoid-based medicine. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. For more information, please visit www.cannabics.com. For the latest updates on Cannabics Pharmaceuticals follow the Company on Twitter @Cannabics, Facebook @CannabicsPharmaceuticals, LinkedIn, and on Instagram @Cannabics_Pharm...